Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S. Corti F, et al. Among authors: amoroso v. BMC Cancer. 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. BMC Cancer. 2023. PMID: 37752423 Free PMC article.
Intra-arterial chemotherapy in elderly patients with invasive bladder cancer.
Mambrini A, Bondavalli C, Caudana R, Amoroso V, Pacetti P, Fiorentini G, Cantore M. Mambrini A, et al. Among authors: amoroso v. Clin Oncol (R Coll Radiol). 2005 Dec;17(8):663-4. doi: 10.1016/j.clon.2005.06.008. Clin Oncol (R Coll Radiol). 2005. PMID: 16372497 No abstract available.
Biomarkers and histology of premalignant and malignant lesions.
Beltrami AC, Puglisi F, Di Lauro V, Scalone S, Amoroso V, Bonura S, Stamerra O, Raiti C, Di Loreto C. Beltrami AC, et al. Among authors: amoroso v. Eur J Cancer Prev. 1996 Oct;5(5):375-6. Eur J Cancer Prev. 1996. PMID: 8972261 Review. No abstract available.
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Berruti A, et al. Among authors: amoroso v. BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184. BMC Cancer. 2014. PMID: 24628963 Free PMC article. Clinical Trial.
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Pozzari M, Maisonneuve P, Spada F, Berruti A, Amoroso V, Cella CA, Laffi A, Pellicori S, Bertani E, Fazio N. Pozzari M, et al. Among authors: amoroso v. Cancer Treat Rev. 2018 Dec;71:39-46. doi: 10.1016/j.ctrv.2018.10.008. Epub 2018 Oct 13. Cancer Treat Rev. 2018. PMID: 30352319 Review.
106 results